AIM ImmunoTech (AIM) Times Interest Earned (2010 - 2026)
AIM ImmunoTech's (AIM) quarterly Times Interest Earned came in at -$2.23 in Q1 2026, up 87.92% YoY from -$1.19 in Q1 2025, and up 78.69% on a QoQ basis from -$10.47 in Q4 2025.
AIM ImmunoTech (AIM) Times Interest Earned (2010 - 2026) Analysis & Trends
AIM ImmunoTech (AIM) has 17 years of Times Interest Earned data on file, last reported at -$2.23 in Q1 2026.
- Quarterly Times Interest Earned rose 87.92% year-over-year to -$2.23 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$10.29 (up 88.58% YoY) and the FY2025 annual result came in at -$0.25, up 46.01% from the prior year.
- Times Interest Earned advanced to -$2.23 in Q1 2026, from -$10.47 in the prior quarter.
- In the past five years, Times Interest Earned ranged from a high of -$1.16 in Q2 2025 to a low of -$102.22 in Q4 2023.
- A 5-year average of -$25.79 and a median of -$19.56 in 2022 frame the typical range for Times Interest Earned.
- Annual changes were most pronounced in 2024 — Times Interest Earned jumped 94.87% — and 2025, when it plunged 728.54%.
- Tracing AIM's Times Interest Earned over 5 years: stood at -$72.16 in 2022, then tumbled by 41.66% to -$102.22 in 2023, then jumped by 56.61% to -$44.36 in 2024, then soared by 76.4% to -$10.47 in 2025, then jumped by 78.69% to -$2.23 in 2026.
- The last three Times Interest Earned figures came in at -$2.23 (Q1 2026), -$10.47 (Q4 2025), and -$13.02 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.18 |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 2.82 |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -0.08 |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 1.42 |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 76.86 |
| 10 | AIM ImmunoTech | 4.34 Mn | -5.62 Mn | 21,000.00 | -11.91 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -0.97 |
| Mar 31, 2026 | -2.23 |
| Dec 31, 2025 | -10.47 |
| Sep 30, 2025 | -13.02 |
| Jun 30, 2025 | -1.16 |
| Mar 31, 2025 | -18.46 |
| Dec 31, 2024 | -44.36 |
| Sep 30, 2024 | -20.50 |
| Jun 30, 2024 | -1.40 |
| Mar 31, 2024 | -2.23 |
| Dec 31, 2023 | -102.22 |
| Sep 30, 2023 | -40.79 |
| Jun 30, 2023 | -27.31 |
| Mar 31, 2023 | -21.48 |
| Dec 31, 2022 | -72.16 |
| Sep 30, 2022 | -27.75 |
| Jun 30, 2022 | -19.56 |
| Mar 31, 2022 | -13.41 |
| Sep 30, 2021 | -3.49 |
| Jun 30, 2021 | -3.81 |